Repeat and Relapsing Peritonitis Microbiological Trends and Outcomes: A 21-Year Single-Center Experience.

IF 1.7 Q3 UROLOGY & NEPHROLOGY
International Journal of Nephrology Pub Date : 2021-01-30 eCollection Date: 2021-01-01 DOI:10.1155/2021/6662488
Marina Reis, Catarina Ribeiro, Ana Marta Gomes, Clara Santos, Daniela Lopes, João Carlos Fernandes
{"title":"Repeat and Relapsing Peritonitis Microbiological Trends and Outcomes: A 21-Year Single-Center Experience.","authors":"Marina Reis,&nbsp;Catarina Ribeiro,&nbsp;Ana Marta Gomes,&nbsp;Clara Santos,&nbsp;Daniela Lopes,&nbsp;João Carlos Fernandes","doi":"10.1155/2021/6662488","DOIUrl":null,"url":null,"abstract":"<p><p>Peritonitis is a major peritoneal dialysis complication. Despite a high cure rate, relapsing and repeat peritonitis is associated with Tenckhoff catheter biofilm and multiple episodes of peritoneal damage. In relapsing peritonitis, prompt catheter removal is mandatory; otherwise, in repeat peritonitis, there is not a clear indication for catheter removal. It is questionable if the approach to removal should be different. There are few recent data on repeat and relapsing peritonitis microbiology and clinical outcomes since most studies are from the past decade. This study evaluates the microbiology, clinical outcomes, and impact of relapsing and repeat peritonitis on technique survival and the impact of catheter removal in development of further peritonitis episodes by the same microorganism. We developed a single-center retrospective study from 1998 to 2019 that compared repeat and relapsing peritonitis with a control group in terms of causative microorganisms, cure rate, catheter removal, and permanent and temporary transfer to hemodialysis. We also compared repeat and relapsing peritonitis clinical outcomes when Tenckhoff catheter was not removed. Comparing to the control group, the repeat/relapsing group had a higher cure rate (80.4% <i>versus</i> 74.5%, <i>p</i>=0.01) and lower rate of hospitalization (10.9% versus 27.7%, <i>p</i>=0.01). Technique survival was superior in the repeat/relapsing group (log rank = 4.5, <i>p</i>=0.03). Gram-positive peritonitis was more common in the repeat/relapsing group especially <i>Streptococci viridans</i> (43.5% versus 21.3%, <i>p</i>=0.01) and Gram-negatives in the control group (26.6% vs 9.0%, <i>p</i>=0.02). When the Tenckhoff catheter was not removed after a repeat episode, 58.6% developed a new repeat/relapsing episode versus 60.0% in the relapsing group. Although repeat and relapsing peritonitis have a higher cure rate, it leads to further episodes of peritonitis and consequent morbidity. When Tenckhoff catheter was not removed, the probability of another peritonitis episode by the same microorganism is similar in repeat and relapsing peritonitis.</p>","PeriodicalId":14177,"journal":{"name":"International Journal of Nephrology","volume":"2021 ","pages":"6662488"},"PeriodicalIF":1.7000,"publicationDate":"2021-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867458/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/6662488","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Peritonitis is a major peritoneal dialysis complication. Despite a high cure rate, relapsing and repeat peritonitis is associated with Tenckhoff catheter biofilm and multiple episodes of peritoneal damage. In relapsing peritonitis, prompt catheter removal is mandatory; otherwise, in repeat peritonitis, there is not a clear indication for catheter removal. It is questionable if the approach to removal should be different. There are few recent data on repeat and relapsing peritonitis microbiology and clinical outcomes since most studies are from the past decade. This study evaluates the microbiology, clinical outcomes, and impact of relapsing and repeat peritonitis on technique survival and the impact of catheter removal in development of further peritonitis episodes by the same microorganism. We developed a single-center retrospective study from 1998 to 2019 that compared repeat and relapsing peritonitis with a control group in terms of causative microorganisms, cure rate, catheter removal, and permanent and temporary transfer to hemodialysis. We also compared repeat and relapsing peritonitis clinical outcomes when Tenckhoff catheter was not removed. Comparing to the control group, the repeat/relapsing group had a higher cure rate (80.4% versus 74.5%, p=0.01) and lower rate of hospitalization (10.9% versus 27.7%, p=0.01). Technique survival was superior in the repeat/relapsing group (log rank = 4.5, p=0.03). Gram-positive peritonitis was more common in the repeat/relapsing group especially Streptococci viridans (43.5% versus 21.3%, p=0.01) and Gram-negatives in the control group (26.6% vs 9.0%, p=0.02). When the Tenckhoff catheter was not removed after a repeat episode, 58.6% developed a new repeat/relapsing episode versus 60.0% in the relapsing group. Although repeat and relapsing peritonitis have a higher cure rate, it leads to further episodes of peritonitis and consequent morbidity. When Tenckhoff catheter was not removed, the probability of another peritonitis episode by the same microorganism is similar in repeat and relapsing peritonitis.

Abstract Image

Abstract Image

Abstract Image

重复和复发腹膜炎微生物趋势和结果:21年单中心经验。
腹膜炎是腹膜透析的主要并发症。尽管治愈率很高,但复发和重复腹膜炎与Tenckhoff导管生物膜和多次腹膜损伤有关。复发性腹膜炎必须及时拔除导管;否则,在重复腹膜炎中,没有明确的导管拔除指征。移除的方法是否应该有所不同,这是值得怀疑的。由于大多数研究都是在过去的十年中进行的,因此最近关于重复和复发腹膜炎微生物学和临床结果的数据很少。本研究评估了微生物学、临床结果、复发和重复腹膜炎对技术生存的影响,以及同一微生物对进一步腹膜炎发作的导管拔除的影响。我们开展了一项1998年至2019年的单中心回顾性研究,比较了重复和复发性腹膜炎与对照组在致病微生物、治愈率、拔管以及永久和暂时转移到血液透析方面的差异。我们还比较了未拔除Tenckhoff导尿管时反复和复发性腹膜炎的临床结果。与对照组相比,重复/复发组治愈率较高(80.4%比74.5%,p=0.01),住院率较低(10.9%比27.7%,p=0.01)。重复/复发组的技术生存率更高(log rank = 4.5, p=0.03)。革兰氏阳性腹膜炎在重复/复发组中更为常见,尤其是翠绿链球菌(43.5%比21.3%,p=0.01),革兰氏阴性腹膜炎在对照组中更为常见(26.6%比9.0%,p=0.02)。当重复发作后不拔除Tenckhoff导管时,58.6%的患者出现新的重复/复发发作,而复发组为60.0%。虽然反复和复发性腹膜炎有较高的治愈率,但它会导致腹膜炎的进一步发作和随之而来的发病率。当Tenckhoff导管未取出时,同一微生物再次发生腹膜炎的概率在重复和复发性腹膜炎中相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Nephrology
International Journal of Nephrology UROLOGY & NEPHROLOGY-
CiteScore
3.40
自引率
4.80%
发文量
44
审稿时长
17 weeks
期刊介绍: International Journal of Nephrology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on the prevention, diagnosis, and management of kidney diseases and associated disorders. The journal welcomes submissions related to cell biology, developmental biology, genetics, immunology, pathology, pathophysiology of renal disease and progression, clinical nephrology, dialysis, and transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信